Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITEIT LEIDEN currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is highly decentralized, involving 4 distinct examiners and 4 distinct art units. This suggests a broad range of technical subject matter that spans multiple specialized divisions at the USPTO, requiring a diverse set of legal and technical arguments to advance the portfolio.
KRISHNAN, GANAPATHY is the busiest examiner for the university, holding 1 pending office action. Because there are 4 pending office actions in total, each of the 4 distinct examiners is responsible for exactly one action. This distribution means that no single examiner or art unit has a dominant influence over the university's current patent prosecution, which may reduce the risk of a single examiner's bias affecting the entire portfolio.
The involvement of 4 distinct art units indicates that the university's innovations in Biotechnology & Pharmaceuticals are being evaluated by four different technical teams. Practitioners must manage four separate examiner relationships simultaneously. With 1 pending office action assigned to each examiner, the university faces a diverse set of procedural and technical requirements across its active portfolio. This decentralized structure requires careful coordination to ensure consistency in prosecution strategy across the 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| KWAK, DEAN P | 1 | 58.7% | +37.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263335 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928339 | ASSEMBLIES AND METHODS | KWAK, DEAN P | 9d overdue |
| 18359526 | DNA-STABILISED METAL CLUSTER BASED NUCLEIC ACID-SENSOR WITH DISTINCT EMISSION COLOUR AND INTENSITY CHANGE UPON TARGET RECOGNITION | CHEN, STACY BROWN | 50d |
| 18263335 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1658 | 1 |
| 1672 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553278 | INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE (NNMT) | KRISHNAN, GANAPATHY | 1693 | §103 | Final Rejection | 28d overdue | Pending | Sep 29, 2023 |
| 18263335 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | KOMATSU, LI N | 1658 | §102§112 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18359526 | DNA-STABILISED METAL CLUSTER BASED NUCLEIC ACID-SENSOR WITH DISTINCT EMISSION COLOUR AND INTENSITY CHANGE UPON TARGET RECOGNITION | CHEN, STACY BROWN | 1672 | §102 | Final Rejection | 50d | Pending | Jul 26, 2023 |
| 17928339 | ASSEMBLIES AND METHODS | KWAK, DEAN P | 1798 | §103 | Non-Final OA | 9d overdue | Pending | Nov 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial